The company’s ROE target (>20%) and gearing target (<130%) were unchanged. Leipurin
machine operations (Vulganus) and Kauko business could be sold in near future. Dividend policy remains unchanged. New long term annual sales growth target is 5-10%. The company’s full year 2021 EBIT guidance is still EUR 30-36m (unchanged). Annual EPS could be EUR 1.20, if the company is able to reach its financial targets according to our analysis. Consensus EPS for 2021 is EUR 0.89. We have a fair value range of EUR 11.2-13.8 for the share.
Aktuellt
SENASTE
